X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6250) 6250
Newsletter (57) 57
Book Chapter (8) 8
Magazine Article (2) 2
Newspaper Article (2) 2
Book Review (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4726) 4726
male (2595) 2595
animals (2367) 2367
pyrimidines - pharmacokinetics (2060) 2060
pharmacology & pharmacy (2030) 2030
female (1968) 1968
pyrimidines - pharmacology (1870) 1870
pyrimidines - therapeutic use (1723) 1723
adult (1394) 1394
pyrimidines - administration & dosage (1362) 1362
middle aged (1299) 1299
oncology (1251) 1251
pharmacokinetics (1242) 1242
pyrimidines - adverse effects (1022) 1022
mice (996) 996
imatinib mesylate (952) 952
aged (916) 916
rats (879) 879
cancer (799) 799
pyrimidines - chemistry (751) 751
benzamides (740) 740
dose-response relationship, drug (739) 739
pyrimidines (736) 736
treatment outcome (703) 703
pyrimidines - blood (688) 688
chemistry, medicinal (654) 654
administration, oral (653) 653
antineoplastic agents - therapeutic use (609) 609
analysis (577) 577
voriconazole (577) 577
research (546) 546
safety (515) 515
cell line, tumor (492) 492
piperazines - therapeutic use (483) 483
imatinib (478) 478
antineoplastic agents - pharmacology (477) 477
care and treatment (469) 469
young adult (466) 466
medicine & public health (464) 464
drug therapy (463) 463
hematology (456) 456
antineoplastic agents - pharmacokinetics (453) 453
drug interactions (451) 451
structure-activity relationship (445) 445
protein kinase inhibitors - therapeutic use (441) 441
therapy (426) 426
protein kinase inhibitors - pharmacology (419) 419
efficacy (412) 412
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (411) 411
pharmacology/toxicology (400) 400
biochemistry & molecular biology (388) 388
chronic myeloid-leukemia (383) 383
pharmacology (379) 379
pyrimidines - metabolism (366) 366
adolescent (364) 364
aged, 80 and over (359) 359
expression (354) 354
in-vitro (353) 353
piperazines - pharmacokinetics (353) 353
pyrimidines - chemical synthesis (351) 351
rats, sprague-dawley (345) 345
metabolism (344) 344
rosuvastatin calcium (338) 338
chemotherapy (332) 332
area under curve (325) 325
piperazines - pharmacology (322) 322
protein kinase inhibitors - pharmacokinetics (322) 322
health aspects (316) 316
triazoles - pharmacokinetics (316) 316
protein-tyrosine kinases - antagonists & inhibitors (311) 311
antineoplastic agents - administration & dosage (302) 302
leukemia (297) 297
time factors (294) 294
chronic myelogenous leukemia (293) 293
tumors (284) 284
biological availability (283) 283
clinical trials (283) 283
sulfonamides - therapeutic use (283) 283
kinases (277) 277
sulfonamides - pharmacokinetics (277) 277
antineoplastic agents (276) 276
drug administration schedule (275) 275
mutation (274) 274
antineoplastic agents - adverse effects (273) 273
dasatinib (271) 271
drugs (271) 271
resistance (271) 271
tyrosine kinase inhibitor (268) 268
inhibitors (262) 262
neoplasms - drug therapy (262) 262
double-blind method (260) 260
antifungal agents - pharmacokinetics (257) 257
cell proliferation - drug effects (253) 253
microbiology (252) 252
dosage and administration (250) 250
antimitotic agents (249) 249
half-life (249) 249
piperazines - administration & dosage (249) 249
clinical trials as topic (248) 248
chemistry, organic (244) 244
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6232) 6232
Japanese (58) 58
German (29) 29
French (21) 21
Chinese (12) 12
Spanish (8) 8
Russian (7) 7
Danish (4) 4
Czech (3) 3
Dutch (3) 3
Norwegian (3) 3
Hungarian (2) 2
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
... of approximately 1.8 log 10  copies ml −1 , and a pharmacokinetic/pharmacodynamic (PK/PD) relationship was identified and characterized. Furthermore, no NNRTI resistance... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2005, Volume 44, Issue 9, pp. 879 - 894
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2009, Volume 35, Issue 8, pp. 692 - 706
.... Post marketing study commitments have been made upon (accelerated) approval such as additional pharmacokinetic studies in patients with renal- or hepatic impairment... 
Hematology, Oncology and Palliative Medicine | Excretion | Absorption | Metabolism | Tyrosine kinase inhibitors | Distribution | Drug transporters and interactions | CHRONIC MYELOGENOUS LEUKEMIA | RENAL-CELL CARCINOMA | CHRONIC MYELOID-LEUKEMIA | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | CHRONIC MYELOCYTIC-LEUKEMIA | ADVANCED SOLID MALIGNANCIES | IMATINIB MESYLATE GLEEVEC | GASTROINTESTINAL STROMAL TUMORS | CEREBROSPINAL-FLUID PHARMACOKINETICS | CANCER RESISTANCE PROTEIN | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Pyrroles - pharmacokinetics | Humans | Cytochrome P-450 Enzyme System - metabolism | Pyridines - pharmacokinetics | Quinazolines - pharmacokinetics | Biological Availability | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Intestinal Absorption | Thiazoles - pharmacokinetics | Antineoplastic Agents - metabolism | Tissue Distribution | Benzenesulfonates - pharmacokinetics | Drug Interactions | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Piperazines - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Dasatinib | Administration, Oral | Imatinib Mesylate | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Indoles - pharmacokinetics | Protein Kinase Inhibitors - pharmacology | Benzamides | Protein Kinase Inhibitors - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Oncology, Experimental | Cytochrome P-450 | Physiological aspects | Phenols | Research | Phosphotransferases | Protein binding | Cancer | Index Medicus
Journal Article
Antimicrobial agents and chemotherapy, ISSN 1098-6596, 2012, Volume 56, Issue 9, pp. 4793 - 4799
Journal Article
Drug metabolism and disposition, ISSN 1521-009X, 2014, Volume 42, Issue 4, pp. 759 - 773
Journal Article
Journal Article
Analytical and bioanalytical chemistry, ISSN 1618-2650, 2018, Volume 410, Issue 11, pp. 2815 - 2828
Generation of skin distribution profiles and reliable determination of drug molecule concentration in the target region are crucial during the development... 
Biochemistry, general | Skin penetration | Food Science | Quantification | Drug distribution | Mass spectrometry imaging | Human skin | Laboratory Medicine | MALDI-MSI | Chemistry | Analytical Chemistry | Monitoring/Environmental Analysis | Characterization and Evaluation of Materials | CHEMISTRY, ANALYTICAL | HUMAN STRATUM-CORNEUM | BIOCHEMICAL RESEARCH METHODS | PENETRATION | MOLECULAR-SIZE | MICROSCOPY | MASS-SPECTROMETRY | TISSUE-SECTIONS | ATOPIC-DERMATITIS | PERCUTANEOUS-ABSORPTION | PSORIASIS | Pyrroles - pharmacokinetics | Benzamides - pharmacokinetics | Skin - metabolism | Humans | Aminopyridines - pharmacokinetics | Pyridines - pharmacokinetics | Drug Discovery - methods | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Pyrroles - administration & dosage | Piperidines - pharmacokinetics | Pyrazoles - pharmacokinetics | Cyclopropanes - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Aminopyridines - administration & dosage | Piperidines - administration & dosage | Pyridines - administration & dosage | Acetamides - pharmacokinetics | Phosphodiesterase 4 Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Skin Absorption | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Pyrimidines - pharmacokinetics | Administration, Topical | Acetamides - administration & dosage | Pharmaceutical research | Topical medication | Pharmaceutical industry | Innovations | Testing | Formulations | Explants | Psoriasis | Medical treatment | Spatial discrimination | Imaging techniques | Ions | Mass spectroscopy | Desorption | Drug development | Tissues | Dermatitis | Ionization | Lasers | Atopic dermatitis | Imaging | Skin diseases | Skin | Mass spectrometry | Spatial resolution | Physicochemical properties
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 11/2015, Volume 70, Issue 3, pp. 242 - 249
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2013, Volume 53, Issue 10, pp. 1010 - 1019
Journal Article
Journal Article